Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 223Lymphoma, Large B-Cell, Diffuse 208Lymphoma, Non-Hodgkin 148Leukemia, Lymphocytic, Chronic, B-Cell 138Lymphoma, Follicular 130Lymphoma, Mantle-Cell 117Lymphoma, B-Cell, Marginal Zone 78Leukemia 72Burkitt Lymphoma 62Waldenstrom Macroglobulinemia 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Lymphoma, B-Cell 45Recurrence 39Lymphoma, Large-Cell, Immunoblastic 33Hodgkin Disease 26Neoplasms 16Dendritic Cell Sarcoma, Interdigitating 16Lymphoma, Large-Cell, Anaplastic 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Hairy Cell 12Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Prolymphocytic 8Leukemia, Myeloid, Accelerated Phase 8Intraocular Lymphoma 8Neoplasms, Plasma Cell 7Leukemia, Myelomonocytic, Chronic 7

Interventions

Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1siltuximab 1liposomal doxorubicin 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Multi-centric Castleman's Disease × Rituximab × Clear all
NCT00092222 2026-06-01

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡